SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-007405
Filing Date
2019-05-15
Accepted
2019-05-15 16:16:17
Documents
51
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 600205
2 ex31-1.htm EX-31.1 18849
3 ex32-1.htm EX-32.1 7567
  Complete submission text file 0001493152-19-007405.txt   3081352

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE atrx-20190331.xml EX-101.INS 414555
5 XBRL SCHEMA FILE atrx-20190331.xsd EX-101.SCH 45886
6 XBRL CALCULATION FILE atrx-20190331_cal.xml EX-101.CAL 40921
7 XBRL DEFINITION FILE atrx-20190331_def.xml EX-101.DEF 197391
8 XBRL LABEL FILE atrx-20190331_lab.xml EX-101.LAB 296661
9 XBRL PRESENTATION FILE atrx-20190331_pre.xml EX-101.PRE 235294
Mailing Address 4721 EMPEROR BOULEVARD SUITE 350 DURHAM NC 27703
Business Address 4721 EMPEROR BOULEVARD SUITE 350 DURHAM NC 27703 919-578-5901
Adhera Therapeutics, Inc. (Filer) CIK: 0000737207 (see all company filings)

IRS No.: 112658569 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-13789 | Film No.: 19828377
SIC: 2834 Pharmaceutical Preparations